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Abstract In addition to the debilitating fatigue, the
majority of patients with chronic fatigue syndrome (CFS)
experience chronic widespread pain. These pain complaints
show the greatest overlap between CFS and fibromyalgia
(FM). Although the literature provides evidence for central
sensitization as cause for the musculoskeletal pain in FM,
in CFS this evidence is currently lacking, despite the
observed similarities in both diseases. The knowledge
concerning the physiological mechanism of central sensiti-
zation, the pathophysiology and the pain processing in FM,
and the knowledge on the pathophysiology of CFS lead to
the hypothesis that central sensitization is also responsible
for the sustaining pain complaints in CFS. This hypothesis
is based on the hyperalgesia and allodynia reported in CFS,
on the elevated concentrations of nitric oxide presented in
the blood of CFS patients, on the typical personality styles
seen in CFS and on the brain abnormalities shown on brain
images. To examine the present hypothesis more research is
required. Further investigations could use similar protocols
to those already used in studies on pain in FM like, for
example, studies on temporal summation, spatial summa-
tion, the role of psychosocial aspects in chronic pain, etc.
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Introduction
Chronic fatigue syndrome (CFS), as defined by the Centers
for Disease Control and Prevention (CDCP), is a complex
illness characterized by prolonged debilitating fatigue and
multiple non-specific symptoms including headaches, re-
current sore throats, fever, muscle and joint pain, and
neurocognitive complaints [1, 2]. In addition to the chronic
fatigue, widespread and persistent pain is common in
individuals with CFS [3–5]. A population-based study
revealed that 94% of the persons diagnosed with CFS
report muscle aches and pain and 84% report joint pain [6].
Nishikai et al. [7] reported muscle pain in 85 CFS patients
of 114 patients (74.6%). Seventy-four patients (64.9%)
complained of arthralgia. In another study, 24 of 44 patients
suffered from chronic widespread pain [8]. Chronic fatigue
accompanied by chronic musculoskeletal impairments such
as myalgias and arthralgias could be considered an
important subclass of CFS [9]. Evidence supportive of the
clinical importance of widespread pain in CFS has been
provided [10]: chronic pain accounts for up to 34% of the
CFS patients’ self-reported activity limitations and partic-
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ipation restrictions. Chronic pain is more disabling than
chronic fatigue [10].
Given these facts, it may be surprising that the etiology
of these pain complaints has not been studied extensively in
patients with CFS. The systematic literature review by
Meeus et al. [11] shows that only little progress has been
made in understanding chronic widespread pain in patients
with CFS. A few hypotheses have been proposed, but they
have not been studied in depth or relatively little work has
been performed to test these hypotheses. In contrast, a large
body of scientific literature regarding the etiology of
chronic pain complaints in fibromyalgia (FM) is currently
available. The diagnosis of FM is based on the 1990
American College of Rheumatology criteria. Following
these criteria, FM patients present with 11 of 18 positive
tender points and with widespread pain [12]. Validity of
both the definition for CFS and FM has been shown
[12, 13].
Especially, investigations focusing on the phenomenon
“central sensitization” are presented in force in FM. In CFS,
the theory of central sensitization has only been suggested,
to our knowledge [14]. Given the great overlap between
CFS and FM [15] and given the dearth of studies focusing
on the explanation for the chronic widespread pain in
patients with CFS, it would be interesting to propose a
theoretical model for the chronic pain in CFS based on the
current knowledge of CFS and on the evidence for central
sensitization in FM, giving rise to further research on that
matter. Besides the knowledge on chronic pain in FM, it is
necessary to gather knowledge on musculoskeletal pain in
CFS.
The syndromes may overlap, but despite the similarities
between the two syndromes, there are also differences. For
example, immunological dysregulations such as the abnor-
mal 2–5A synthetase/RNase L pathway [16] have been
revealed in CFS but have never been detected in FM
patients. Furthermore, there is not yet any good evidence
for similar pain mechanisms in CFS and FM. Some authors
already found evidence suggesting differences in pain
processing. For example, patterns of functional brain
activity in patients with FM are quite different from those
in patients with CFS.
Patients with CFS, relative to controls, showed signifi-
cantly lower blood perfusion in the brain stem [17, 18].
Patients with FM exhibited significantly lower rCBF levels,
during rest, in the thalamus and the caudate nucleus [19].
Furthermore, Substance P has been found to be elevated in
CSF of FM patients [20] and not in patients with CFS [21].
Therefore, the knowledge on pain in FM cannot be applied
on CFS patients without further study. Based on the
similarities and differences between the two syndromes,
further research on pain in CFS is advised to get an image
of pain processing in the two diseases.
The goal of this article is to provide a rational basis for
future investigations. First, the concept of central sensitisa-
tion as a cause of chronic pain will be explained. This
theoretical background will then be applied to FM and an
overview of the evidence for central sensitization in FM
will follow. Finally, based on the theoretical background
and the findings in FM, the hypothesis concerning central
sensitization in CFS will be unfolded, supported with the
present knowledge on CFS.
Central sensitization
Introduction Pain is a complex perception that is influenced
by prior experience and by the context within which the
noxious stimulus occurs; “nociception” is the physiologic
response to tissue damage or prior tissue damage [22]. The
definition of pain is endorsed by the International Associ-
ation for the Study of Pain: “Pain is an unpleasant sensory
and emotional experience associated with actual or poten-
tial tissue damage, or described in terms of such damage”
[23]. There are a host of physiologic mechanisms by which
injuries lead to nociceptive responses and ultimately to pain
[22]. However, not all nociceptive signals are perceived as
pain and vice versa, not every pain sensation originates
from nociception. Nevertheless, acute pain almost always
originates from nociceptors in somatic or visceral tissue.
Mainly two types of pain receptors are activated by
nociceptive input. These include low-threshold nociceptors
that are connected to fast conducting A-delta pain fibers,
and high-threshold nociceptors that conduct impulses in
slow (unmyelinated) C fibers. Within the dorsal horn of the
spinal cord, these pain fibers synapse with spinal neurons
via synaptic transmission. Many neurotransmitters (i.e.,
glutamate, substance P, etc.) are able to modulate the
postsynaptic responses with further transmission to supra-
spinal sites (thalamus, anterior cingulated cortex, insular
cortex, and somatosensory cortex) via the ascending path-
ways [22, 24, 25].
The simplest form of plasticity in nervous systems is that
repeated noxious stimulation may lead to habituation
(decreased response) or sensitization (increased response)
[26]. Prolonged or strong activity of dorsal horn neurons
caused by repeated or sustained noxious stimulation may
subsequently lead to increased neuronal responsiveness or
central sensitization [25, 27]. Neuroplasticity and subse-
quent CNS sensitization include altered function of chem-
ical, electrophysiological, and pharmacological systems
[22, 28, 29]. These changes cause exaggerated perception
of painful stimuli (hyperalgesia), a perception of innocuous
stimuli as painful (allodynia) and may be involved in the
generation of referred pain and hyperalgesia across multiple
spinal segments [25, 30–33].
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While the exact mechanism by which the spinal cord
becomes sensitized or in “hyperexcitable” state currently
remains somewhat unknown, some contributing factors
have been proposed.
Temporal summation or wind-up “Wind up” refers to a
central spinal mechanism in which repetitive noxious
stimulation results in a slow temporal summation that is
experienced in humans as increased pain [34]. In 1965,
animal experiments showed for the first time that repetitive
C-fiber stimulation could result in a progressive increase of
electrical discharges from the second-order neuron in the
spinal cord [35]. This mechanism of pain amplification in
the spinal cord is related to temporal summation of second
pain or wind-up. Second pain, which is more dull and
strongly related to chronic pain states, is transmitted
through unmyelinated C fibers to dorsal horn nociceptive
neurons. During the C-fibres transmitted stimuli, N-methyl-
D-aspartate (NMDA) receptors of second-order neurons
become activated.
It is well-known that NMDA activation induces calcium
entry into the dorsal horn neurons [36]. Calcium entry into
sensory neurons in the dorsal horn induces activation of
nitric oxide (NO) synthase, leading to the synthesis of NO
[37]. NO can affect the nociceptor terminals and enhance
the release of sensory neuropeptides (in particular, sub-
stance P) from presynaptic neurons, therefore contributing
to the development of hyperalgesia and maintenance of
central sensitization [38]. Substance P (SP) is an important
nociceptive neurotransmitter. It lowers the threshold of
synaptic excitability, resulting in the unmasking of normal-
ly silent interspinal synapses and the sensitization of
second-order spinal neurons [39].
Furthermore, SP can extend for long distances in the
spinal cord and sensitize dorsal horn neurons at a distance
from the initial input locus. This results in an expansion of
receptive fields and the activation of wide dynamic neurons
by non-nociceptive afferent impulses [24].
Wind-up can be elicited in human patients if identical
nociceptive stimuli are applied to the skin or muscles more
often than once every 3 s. The resulting progressive
increase of pain sensations represents wind-up and has
been demonstrated to result from a central rather than a
peripheral nervous system mechanism, because the input
from C nociceptors has been shown to decline or stay the
same with stimulus repetition [40].
Endogenous pain modulatory systems The presence of
several pain inhibitory and facilitatory centers in the
brainstem is well recognized. The dorsolateral funiculus
appears to be a preferred pathway for descending pain
inhibitory systems [41]. Experimental evidence for the
existence of descending inhibitory pathways, and their
connection with central sensitization, include the observa-
tions that bilateral lesions of the dorsolateral funiculus in
the rat led to a significant decrease in latency for paw
withdrawal to noxious stimulus [42]. Similarly, temporary
spinal cord block (lidocaine) caused dorsal horn nociceptive
neurons to expand their receptive fields and their respon-
siveness to afferent input [43]. In addition, selective
chemical lesion of serotonergic inhibitory neurons in
experimentally “inflamed” animals resulted in demonstrable
behavioral “pain” hypersensitivity [42].
The foregoing investigations suggest that disruption of
one or more of the elements of the inhibitory system can
result in, among other things, the equivalent of central
sensitization [44]. One function of the descending inhibi-
tory pathway is to “focus” the excitation of the dorsal horn
neurons. The effect is to generate a more urgent, localized,
and rapid pain signal by suppressing surrounding neuronal
activity [45]. This role is attributed to the “diffuse noxious
inhibitory controls” (DNIC) phenomenon [46]. According
to this model, descending pathways effectively enhance the
biologically valuable pain signal by reducing the level of
irrelevant “noise” in the system.
Facilitatory pathways leading from the brainstem have
also been identified. There is now behavioral evidence that
forebrain centers are capable of exerting powerful clinically
significant influences on various nuclei of the brainstem,
including the nuclei identified as the origin of the
descending facilitatory pathway [44]. The activity in
descending pathways is not constant but can be modulated,
for example, by the level of vigilance or attention and by
stress [47]. Brosschot [48] refers to it as cognitive
emotional sensitization. Forebrain products such as cogni-
tions, emotions, attention, and motivation have influence on
the clinical pain experience [44].
Dubner and Ren [41] rewarded subjects for responding
to a randomly delivered transient tissue threatening periph-
eral stimulus. It was found that sensitization of second-
order pain pathway neurons was directly related to the
strength of attention. The evidence suggests that selective
attention to relevant stimuli activated descending pain
modulatory systems, turning the balance in favor of
facilitation. The dominance of descending facilitation then
led to sensitization of second-order neurons [44]. Behav-
ioral variables such as attention to a potentially threatening
stimulus result in sensitization of dorsal horns spinal cord
neurons. Moreover, behavioral modulation associated with
selective attention to a perceived threat utilizes the same
forebrain and brainstem structures and mechanisms as are
involved in the development, amplification, and mainte-
nance of persistent pain after actual tissue damage and
inflammation [41].
Certain cognitive styles and personality traits have been
associated with amplification of pain and its extension in
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the absence of tissue damage. These include somatization,
catastrophizing, and hypervigilance [49–52]. Thus, via
descending pathways behavioral and cognitive therapies
might also effect synaptic transmission in the spinal cord
and thereby have the capacity to prevent or reverse long-
term changes of synaptic strength in pain pathways [47].
Evidence in FM
Exaggerated pain is common in whiplash and FM patients.
Theoretically, peripheral mechanisms can account for the
pain hypersensitivity. In FM, however, there is no evidence
for peripheral sensitization as the cause of hyperalgesia,
given the absence of real tissue damage. Peripheral
sensitization is defined as a reduction in the threshold of
nociceptive afferent receptors caused by a local change in
the sensitivity of sensory fibers initiated by tissue damage
[53]. Peripheral sensitization almost always depends on
local inflammation, which may lead to decreased nocicep-
tor thresholds. Despite extensive investigations, no tissue
pathology, structural abnormalities, or evidence for a source
of chronic stimulation of pain afferents have been detected
in fibromyalgic patients [54].
Furthermore, FM pain lacks a distinct spatial localization
[55]. This suggests that pathophysiological central mecha-
nisms contribute to or are responsible for FM pain [56].
This has led to the hypothesis that the central nervous
system is hyperexcitable in these patients. Central hyper-
sensitivity could explain exaggerated pain in the presence
of minimal and undetectable tissue damage, in that the
nociceptive signal is amplified by the hyperexcitable
neurons [57].
Pain measurements Studies in patients with chronic pain
after whiplash injury and with FM have demonstrated
exaggerated pain responses after sensory stimulation of
healthy tissues [55, 58–63]. For example, at same level of
thermal stimulation, FM patients perceived pain as 49 and
52% more intense than healthy controls and patients with
low-back pain [61]. After-sensations at 15 s after heat taps
were regarded as painful on 83% of FM patients, compared
to 37% pain reports of healthy controls. The late after-
sensations (2 min after heat stimulation) were rated as
painful in 55 and 5% of FM and control subjects,
respectively [55]. It was not mentioned in the results if all
FM patients were subject to increased sensitivity, but there
were always significant differences between the FM
patients and the healthy controls.
Although most comparisons were made to pain-free
subjects, some researchers, like Julien et al. [61], even
compared the pain responses of FM patients to other pain
patients, such as patients with chronic low-back pain. They
could also report significant differences. Despite the lack of
research into the contribution of psychological factors in
wind-up, these results suggest that input to central
nociceptive pathways is abnormally processed in patients
with FM. Intramuscular electrical stimulation has been used
to assess the efficacy of temporal summation of painful
muscle stimuli. Temporal stimulation was found to be more
pronounced and to cause stronger pain and larger referred
areas in FM patients compared to controls [60].
The increased efficacy of temporal summation in FM has
even so been reproduced with cutaneous heat stimulation
[55] and with cold and heat taps [59]. Facilitated temporal
summation in patients with pain suggests that the efficacy
of central processing is increased (central sensitization) in
these patients [64]. In addition, after-sensation was greater
in magnitude, lasted longer, and was more frequently
painful in patients with FM [55]. The prolonged decay
together with the augmentation provides evidence for the
presence of central sensitization [24, 25]. Immersion of the
arm in circulating noxious cold water resulted in a 49%
more intense pain in FM patients compared to healthy
controls [61]. Further evidence of central sensitization in
FM is seen by enlarged referred pain areas. Sörensen et al.
[60] found that fibromyalgic patients experienced stronger
pain and larger referred areas after intramuscular injection
of hypertonic saline.
Moreover, spatial summation effect during increase of
the stimulation area was found only in patients with FM
and not in healthy controls or in patients with chronic low-
back pain [61]. This indicates that pain inhibitory systems
are not optimally recruited in patients with FM. FM patients
perceived pain at the same intensities and unpleasantness
during the ascending and the descending sessions (fingertip
to shoulder and shoulder to fingertip immersion). In healthy
controls and patients with low-back pain, the noxious
stimulation of a large surface area results in an activation of
a large population of nociceptive afferents that induce
endogenous inhibitory responses, resulting in a decreased
response in the dorsal horn neurons, and subsequently leads
to lower pain intensities afterward.
Given that FM patients experience similar pain intensities
in the descending session after noxious stimulation of the
whole arm, this study clearly demonstrated that FM patients
present with a lack of activation of endogenous inhibitory
systems [61]. Secondly, Lautenbacher and Rollman
[65] showed that tonic painful and non-painful thermal
stimulation of the foot increased the pain thresholds to
electrical stimulation applied to a non-tender point (inner
forearm) in healthy controls but had no effect on patients
with FM. Kosek and Hansson [66] found that tourniquet
ischemic pain in an arm increased the pressure pain
threshold in healthy controls but not in FM patients,
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suggesting once more a deficiency in the latter of a pain-
inhibitory phenomenon termed “diffuse noxious inhibitory
control” (DNIC) [66, 67]. Similarly, aerobic exercise has
been shown to decrease wind-up pain in normal subjects
but increased it in FM patients, suggesting the possibility of
reduced endogenous analgesic mechanisms [68]. Also,
isometric exercise (i.e., hand-grip exercise) resulted in
increased thermal pain ratings and decreased pain thresh-
olds, both ipsilateral and contralateral to the exercised
extremity [69]. These investigations support a general
hypothesis that FM reflects a disorder affecting modulation
of pain sensitivity [66, 67]. In one such scenario, tonic
DNIC is present in the normal situation, and its patholog-
ical absence results in the spontaneous pain and evoked
pain sensitivity associated with FM [34].
Measurements of excitability The results of the above-
mentioned studies, however, are based on pain reports of
the patients and thus subjective in nature, and it was not
clear whether this hypersensitivity was the result of central
mechanisms or whether the hypersensitivity was the cause
of hypervigilance. Banic et al. [57] could provide objective
evidence by quantifying the minimal intensity of transcu-
taneous electrical stimulation of the sural nerve required to
evoke flexion reflex in the biceps femoris. This study
clearly demonstrates that spinal cord neurons are sensitized
in chronic pain after whiplash and in patients with FM;
because the stimuli were delivered at random time intervals
and the latency of EMG response was measured, voluntary
symptom amplification could be ruled out. Moreover, the
electrical stimulation bypasses peripheral receptors.
Cognitive emotional sensitization Patients with FM or other
pain disorders often receive the message that it is “all in
their head”. One construct that has been hypothesized to
explain the pain amplification in FM is that of hypervig-
ilance [34]. This hypothesis of hypervigilance has been
argued by McDermid et al. [70]. FM showed an increased
aversiveness to non-painful stimuli such as loud noise.
Also, Crombez et al. [71] reported significant correlations
between hypervigilance and pain intensity in FM patients.
Furthermore, exposure to stressful situations, including
noise, lights, and weather, is known to exacerbate symp-
toms of FM, including pain [72].
In addition, FM patients with catastrophic thoughts
report increased pain intensities [73–75]. Hassett et al.
[74] found catastrophizing (27% of the variance) and
depression (30% of the variance) to be significant predic-
tors of pain. Finally, kinesiophobia and fear of pain are
related to pain severity in patients with FM [76].
The foregoing relations between emotions or cognitions
and reported pain severity support the hypothesis of
cognitive emotional sensitization in FM.
Central abnormalities in FM FM patients differ from
healthy persons in regional cerebral blood flow (rCBF)
distribution in several brain structures involved in pain
processing and pain modulation both at rest and during
experimental pain induction. Patients with FM exhibited
significantly lower rCBF levels, during rest, in the thalamus
and the caudate nucleus [17]. Dysregulation of thalamic
activity and hypoperfusion of the caudate nucleus may
contribute to the abnormal pain modulation, given the results
of previous investigations [77–79]. In addition to nociceptive
transmission, the thalamus also plays an important role in
pain modulation. Animal studies proved that thalamic
stimulation induces analgesia and lesions of the thalamus
cause hyperalgesia [77, 78].
Similarly, stimulating the caudate nucleus decreases pain
behavior [79]. During pain induction in patients with FM, the
absence of significant thalamic activation and a bilateral
activation of the somatosensory cortices and the right
anterior cingulated cortex was seen [80]. The patterns of
cortical activation may be characteristic of patients with
allodynia, and pain-induced activation of the right anterior
cingulated cortex is associated with the use of maladaptive
coping strategies [81]. Patients recruited by Bradley et al.
[80] indeed reported significantly greater use of emotion-
focused coping strategies (e.g., praying and hoping) during
pressure stimulation. In addition, increased right frontal brain
activity seemed related to increased pain sensitivity [82].
Furthermore, FM patients are characterized by relatively
high cerebrospinal fluid levels of substance P [20]. This
finding indicates that abnormal brain activity in persons
with FM is associated with abnormal CSF levels of a
neuropeptide involved in pain transmission [80]. In addi-
tion, it is shown that a subgroup of FM patients present
with mycoplasma infections [83]. Infection triggers the
release of the pro-inflammatory cytokine interleukin-1β,
which is known to play a major role in inducing cyclo-
oxygenase-2 (COX-2) and prostaglandin E2 expression in
the central nervous system [84].
Peripheral nerve terminals can be sensitized by elevated
COX-2 amounts and prostaglandin E2. Peripheral infections
are even able to activate spinal cord glia, leading to the release
of NO and proinflammatory cytokines, enhancing the pain
response [85]. Physiological symptoms, such as pain, can be
explained by these mechanisms (“sickness response”).
Central sensitization in CFS?
Direct evidence supporting the central sensitization hypothe-
sis in CFS patients is currently lacking. But the present
knowledge concerning CFS is suggestive of a central process
similar to that seen in FM, given the great overlap between the
two diseases and the observed similarities.
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First, lower pain thresholds at different sites (hyperalgesia)
are reported in patients with CFS, compared to controls [86,
87]. Similar to FM, the lack of peripheral tissue damage and
the lack of a distinct localization of the pain complaints are
suggestive of a central abnormality responsible for the
chronic widespread pain. To our knowledge, there are no
investigations that focused on abnormal wind-up, temporal
summation, or spatial summation in CFS, to collect evidence
for central sensitization in CFS. Yet, evidence of a
dysfunctional central anti-nociceptive mechanism in CFS
has been proved by Whiteside et al. [88]. They reported a
decrease of pain threshold in patients with CFS after graded
exercise, while healthy controls present an increased pain
threshold. These findings are similar to those of Vierck et al.
[68] in FM patients.
Secondly, the frequently reported opportunistic infec-
tions [89, 90] may lead to the “sickness response” and
complies with the central sensitization hypothesis, as
explained above. Indeed, elevated NO levels have been
documented in CFS patients [91]. As earlier mentioned, NO
plays an important role in the history of central sensitization
and, therefore, central sensitization caused by NO would be
likely in patients with CFS. The release of excessive
amounts of Substance P in the CSF, however, could not
be documented in patients with CFS, in contrast to FM
patients [21]. The CFS patients in this study, however, did
not experience chronic widespread pain, and it is not clear
if they fulfilled the 1994 CDC criteria [2]. Given that 70%
of the CFS patients do fulfill the ACR criteria for
widespread pain [12], it is striking that the patients included
in the investigation of Evengard et al. [21] (focused on the
source of pain) did not report these pain complaints. Further
research on that matter should analyze the CSF of CFS
patients (fulfilling the Fukuda criteria) suffering from
chronic widespread pain.
A third important argument in the central sensitization
theory for CFS concerns the cognitive, psychological, and
behavioral changes in patients diagnosed with CFS. CFS
patients often present with depression [6, 92], catastrophizing
[93, 94], somatization [95, 96], and kinesiophobia or fear
avoidance [97–99]. In CFS, it is known that these
psychosocial aspects are important factors in maintaining
the complaints of CFS. These cognitions and emotions are
able to influence pain perception via modulation of the
descending pathways [44]. Furthermore, these “cognitive
styles” and “personality traits” have earlier been mentioned
to be associated with the amplification and the extension of
pain [49–52].
Finally, brain imaging already provided evidence for
altered brain activity in CFS. Patterns of functional brain
activity in patients with FM are quite different from those in
patients with CFS. Patients with CFS, relative to controls,
showed significantly lower blood perfusion in the brain stem
[17, 18]. Patients with FM exhibited significantly lower
rCBF levels, during rest, in the thalamus and the caudate
nucleus [19]. However, the areas are different in FM and in
CFS; both the affected areas could be related to central pain
processing. Low brain stem rCBF levels may contribute to
abnormal function of the locus ceruleus in patients with CFS.
The locus ceruleus is involved in controlling descending
anti-nociceptive pathways from the brain to the spinal dorsal
horn [56]. In consequence, pain experiences of patients with
CFS may be related to low resting state levels of functional
activity in the brain stem [80].
Conclusion
Chronic widespread pain can be the consequence of central
sensitization. Central sensitization is known as an increased
central neuronal responsiveness and causes hyperalgesia,
allodynia, and referred pain and hyperalgesia across
multiple spinal segments, leading to chronic widespread
pain. Possible triggers for sensitization of the spinal cord
have extensively been discussed, such as wind-up or
temporal summation, dysregulated descending inhibitory
pathways, and upregulated facilitatory modulation. Wind-
up or temporal summation is the result of repetitive noxious
stimuli, leading to an increase in electrical discharges in the
dorsal horn. Inhibitory modulation can be impaired by
abnormalities in the central nervous system and the
facilitatory pain pathways can be stimulated by certain
behavioral and cognitive factors.
This theoretical background can be applied to FM. In
FM, studies already provided evidence for central sensiti-
zation as the cause of chronic pain. Temporal summation
was found to be more facilitated, and the inhibitory pain
modulation seemed impaired in FM patients. These find-
ings can explain the chronic spontaneous pain in FM.
Furthermore, some central abnormalities could be exam-
ined/objectified in FM: 1) hyperexcitability of the spinal
cord, 2) decreased perfusion of pain-related brain struc-
tures, and 3) high levels of substance P in CSF. In addition,
FM patients often present with pain hypervigilance,
maladaptive coping strategies, and catastrophic thoughts,
leading to cognitive central sensitization.
Based on the knowledge on central sensitization, on FM
and on CFS, it is suggested that chronic widespread pain in
CFS is the consequence of central sensitization. There are
arguments and probable mechanisms that could explain this
phenomenon in CFS. Also, in other chronic pain popula-
tions, central sensitization may play a key role. In fact,
there are many similarities between CFS patients and other
chronic pain populations such as patients with chronic low-
back pain, whiplash, FM, etc. The psychosocial factors, for
example, have been proved to contribute to pain perception
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in these different pain populations. But the specific nature
of CFS such as the immunological abnormalities, elevated
NO amounts, preceding infections etc., invites further
research, in particular, on the possible contributory role of
these abnormalities to pain processing in CFS.
In FM, many researches have been conducted to prove
the theory of central sensitization. In CFS, however, it
sticks to “supposing.” To give a scientific basis to the
theory, the protocols applied in FM investigations could be
used for patients with CFS. It would, for example, be
interesting to test the efficacy of temporal summation in
CFS. The inhibitory control of pain could be another point
of interest. The influence of exercise on pain tolerance has
already been studied in CFS [88], however, on a relatively
small sample. On the contrary, spatial summation has, to
our knowledge, never been investigated in CFS. Further-
more, the role of depression, hypervigilance, kinesiophobia,
catastrophising, etc. on chronic pain in CFS requires further
research. To obtain more direct and objective information
on central sensitization, the protocol described by Banic et al.
[57] could be used to test the sensitivity of the central
nervous system. Clearly, there are many possible research
areas to test the hypothesis, but there is still a long way to
go to elucidate the nature of the chronic pain in CFS.
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